
    
      PRIMARY OBJECTIVES:

      I. To improve overall survival in patients with post-transplant relapse of myeloid
      malignancies.

      OUTLINE:

      Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7. Treatment
      repeats every 28 days for 6 courses in the absence of disease progression or unacceptable
      toxicity.
    
  